Leerink Partners analyst Paul Matteis sees AC Immune SA (NASDAQ: ACIU) under pressure today after Eli Lilly announced that announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE